Stocksigma LogoStocksigma Logo

Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion

Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 million for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 million and

Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion

Marksans Pharma Ltd · Financial Result · 04 Nov 2026, 7:05 pm

Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 million for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 million and 11.8% QoQ. Consolidated net profit attributable to owners rose 43.8% YoY to ₹1,413.12 million (₹982.50 million in Q2 FY26), with basic EPS improving to ₹3.12 from ₹2.17. For H1 FY27, operating revenue reached ₹17,809.65 million with PAT at ₹2,984.79 million. Inorganic European expansion continued via 100% acquisitions of Netherlands-based QliniQ B.V. (€7.50 million) and Germany-based ABCnow GmbH (€1.10 million).

Original exchange filing (PDF)

More announcements from Marksans Pharma Ltd

All Marksans Pharma Ltd announcements